A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

Most current approaches rely on adding nuclear localization signal (NLS) motifs to the ends of Cas9 to facilitate nuclear entry. However, this method is inefficient, and much of the Cas9 that is ...

Over the past two decades, synthetic biology has fueled advancements across a broad range of disciplines, including agriculture, bioremediation, biofuel production, and chemical manufacturing. Today, ...

TG Therapeutics (NASDAQ: TGTX) will release its quarterly earnings report on Monday, 2025-11-03. Here's a brief overview for investors ahead of the announcement. Analysts anticipate TG Therapeutics to ...

Seven years after the first gene-edited babies were revealed, biotech startup Manhattan Genomics is reviving the idea of ...

The clinical hold follows Intellia's disclosure that it paused dosing in two Phase III trials after a patient experienced a serious adverse event.

Cystic fibrosis (CF) therapeutics refer to treatments designed to manage and alleviate the symptoms of cystic fibrosis, a ...

NEW YORK -- Rap mogul Sean "Diddy" Combs was sentenced on Friday to more than four years in prison after a jury found him guilty of two counts of transportation to engage in prostitution in July. He ...

A research team has successfully engineered a japonica rice variety using CRISPR/Cas9 to simultaneously optimize plant ...

ICHORtec GmbH is pleased to announce an expanded research collaboration with the laboratory of Professor Gregory A. Newby in the Department of Genetic Medicine at the Johns Hopkins University School ...

In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...